Inclisiran is a novel small interfering RNA lipid-lowering drug that through targeted delivery to the liver,specifically inhibits the synthesis of the proprotein convertase subtilisin/kexin type 9 in liver cells,thereby reducing low-density lipoprotein cholesterol levels.At present,the Food and Drug Administration and the National Medical Products Administration have officially approved the marketing of inclisiran.This article provides a review of the mechanism,clinical application efficacy and safety of inclisiran,in order to provide reference for lipid-lowering treatment.
Small interfering RNAInclisiranProprotein convertase subtilisin/kexin type 9Low-density lipoprotein cholesterol
NETL
NSTL
万方数据
